

References

I-233

1. Deschenes G, Cochat P, Magen D, et al. ILLUMINATE-B a phase 3 open-label study to evaluate lumasiran, an RNAi therapeutic, in young children with primary hyperoxaluria type 1 (PH1). Presented at: ASN 2020 Annual Meeting; October 2020.
2. Liebow A, Li X, Racie T, et al. An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria. *J Am Soc Nephrol*. 2017;28:494-503.
3. Frishberg Y, Cochat P, Talamudupula S, McGregor T, & Tamimi N. ILLUMINATE-C: A phase 3 single-arm study to evaluate efficacy, safety, pharmacokinetics, and pharmacodynamics of lumasiran in patients with advanced primary hyperoxaluria type 1. Poster presentation.
4. Oxulumo (lumasiran), injection, for subcutaneous use [package insert]. Alnylam Pharmaceuticals, Inc. Cambridge, MA. Revised 11/2020.
5. Hayes, Inc. Hayes Emerging Technology Report. Lumisiran. Lansdale, PA: Hayes, Inc.; 11/2020.
6. Clinical Pharmacology™ 2020. Tampa FL: Gold Standard, Inc. Lumisiran.
7. Micromedex DrugDex Compendium®. 2020. Lumisiran.
8. [Lumisiran] In: AHFS Drug Information Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists. Updated [2020].
9. Lexi-Drugs. Hudson, OH: Lexicomp, 2020.